Open Access

Prognostic and clinical significance of subcellular CDC27 for patients with rectal adenocarcinoma treated with adjuvant chemotherapy

  • Authors:
    • Chia-Lin Chang
    • Kevin Chih‑Yang Huang
    • Tsung-Wei Chen
    • William Tzu‑Liang Chen
    • Hsuan-Hua Huang
    • Ya-Ling Liu
    • Chia-Hui Kuo
    • K.S. Clifford Chao
    • Tao-Wei Ke
    • Shu-Fen Chiang
  • View Affiliations

  • Published online on: May 31, 2022     https://doi.org/10.3892/ol.2022.13358
  • Article Number: 238
  • Copyright: © Chang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Rectal adenocarcinoma (READ) constitutes one‑third of newly diagnosed colorectal cancer cases. Surgery, chemotherapy and concurrent chemoradiotherapy are the main treatments to improve patient outcomes for READ. However, patients with READ receiving these treatments eventually relapse, leading to a poor survival outcome. The present study collected surgical specimens from patients with READ and determined that cytoplasmic cell division cycle 27 (CDC27) expression was associated with the risk of lymph node metastasis and distant metastasis. Nuclear CDC27 expression was negatively associated with 5‑year disease‑free survival (DFS) and 5‑year overall survival (OS) rates. Multivariate Cox proportional regression analysis showed that nuclear CDC27 was an independent prognostic factor in the patients with READ, especially in those treated with adjuvant chemotherapy. High nuclear CDC27 expression was significantly associated with poorer 5‑year DFS (HR, 2.106; 95% CI, 1.275‑3.570; P=0.003) and 5‑year OS (HR, 2.369; 95% CI, 1.270‑4.6810; P=0.005) rates. The data indicated that cytoplasmic CDC27 expression could affect tumor progression and that it plays an important role in metastasis. Nuclear CDC27 expression was markedly associated with poorer survival outcomes and was an independent prognostic factor in patients with postoperative adjuvant chemotherapy‑treated READ. Thus, CDC27 expression serves as a potential prognostic marker for rectal tumor progression and chemotherapy treatment.

Related Articles

Journal Cover

July-2022
Volume 24 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chang C, Huang KC, Chen T, Chen WT, Huang H, Liu Y, Kuo C, Chao KC, Ke T, Chiang S, Chiang S, et al: Prognostic and clinical significance of subcellular CDC27 for patients with rectal adenocarcinoma treated with adjuvant chemotherapy. Oncol Lett 24: 238, 2022
APA
Chang, C., Huang, K.C., Chen, T., Chen, W.T., Huang, H., Liu, Y. ... Chiang, S. (2022). Prognostic and clinical significance of subcellular CDC27 for patients with rectal adenocarcinoma treated with adjuvant chemotherapy. Oncology Letters, 24, 238. https://doi.org/10.3892/ol.2022.13358
MLA
Chang, C., Huang, K. C., Chen, T., Chen, W. T., Huang, H., Liu, Y., Kuo, C., Chao, K. C., Ke, T., Chiang, S."Prognostic and clinical significance of subcellular CDC27 for patients with rectal adenocarcinoma treated with adjuvant chemotherapy". Oncology Letters 24.1 (2022): 238.
Chicago
Chang, C., Huang, K. C., Chen, T., Chen, W. T., Huang, H., Liu, Y., Kuo, C., Chao, K. C., Ke, T., Chiang, S."Prognostic and clinical significance of subcellular CDC27 for patients with rectal adenocarcinoma treated with adjuvant chemotherapy". Oncology Letters 24, no. 1 (2022): 238. https://doi.org/10.3892/ol.2022.13358